Objective To evaluate the efficacy and safety of Yangyin Yiqi Huoxue Granule(养阴益气活血颗粒,YYHG)in the treatment of ischemic stroke(IS)patients with qi-yin deficiency and blood stasis syndrome(QYDBSS),and to explore its effective dosage.Methods The total of 288 patients were randomly assigned to the YYHG high-dose,YYHG low-dose,positive control(administered Xiaoshuantong Granule,XSTG,消栓通颗粒),or placebo control(administered inert granule)groups(72 cases per group)by software-drived competitive block randomization.The trial was conducted for a 28-day period,with a 180-day follow-up period.The primary outcome was the comprehensive curative evaluation,and secondary outcomes were the National Institute of Health Stroke Scale(NIHSS)score,Barthel activities of daily living(ADL)index score,the quality of life index(QLI)score,and the Chinese medicine syndrome(CMS)score.All analyses were done on an intention-to-treat basis.The clinical safety was also assessed.Results The total of 288 participants were recruited between June 1,2008 and September 30,2009,and 287 patients received intervention;the treatment groups were well balanced at baseline.The comprehensive cure rates of YYHG high-dose,low-dose,positive and placebo control groups were 63.38%,31.94%,36.11%and 6.14%,respectively;there was a statistical difference between the two groups(P<0.01),while the high-dose YYHG treatment group was significantly higher than the other 3 groups(P<0.01).The improvement of NIHSS,ADL,QLI and CMS scores of the YYHG high-dose and low-dose groups was significantly better than that of the positive control group and the placebo control group(P<0.05).In terms of improving the classification of the NIHSS scale and the assessment of the ADL scale,the YYHG high-dose group was significantly better than the other three groups(P<0.05),and the YYHG low-dose group was better than the placebo control group(P<0.01).At the same time,except for the QLI score,the high-dose group was better than the low-dose group(P<0.05).In terms of saf
Objective： To observe the effects of Danhong Injection （丹红注射液） and its main components, including daiclzein and hydroxysafflor yellow A （HSYA）, on the anticoagulation, fibrinolysis, anti-apoptosis in hypoxia model of vein endothelial cells （VECs）. Methods： VECs were prepared and were put in a hypoxia environment, which consisted of mixed gas of 95% N2 and 5% CO2 mixed gas, when reached confluent culture. Five groups used different treatments, including normal control group, hypoxia group, daiclzein group, HSYA group and Danhong Injection group. The VECs were identified by fluorescence double labeling methods. The morphology was observed by a phase contrast microscopy. The effects of Danhong Injection, daiclzein and HSYA on 6 keto prostaglandin F1α （6-keto-PGF1 α） level was measured by the method of radioimmunoassay （RIA）. Superoxide dismutase （SOD） activity was tested by water soluble tetrazolium salt. The content of malondialdehyde （MDA） was measured by thiobarbituric acid. The activities of tissue-type plasminogen activator （t-PA） and plasminogen activator inhibitor （PAl） were measured by the method of chromogenic substrate. The contents of endothelin （ET） and nitric oxide （NO） were detected by non-equilibrium RIA and enzyme- linked immunosorbent assay. Cells apoptosis rate was determined by flow cytometry. Results： Compared with the normal control group, the floating cells number, PAl activity, ET and MDA contents, and cells apoptosis rate in the culture solution of hypoxia group were all significantly increased, whereas the 6-keto-PGF1 α and NO contents, and t-PA and SOD activities were decreased significantly （P〈0.01）. Compared with the hypoxia group, Danhong Injection markedly increased the 6-keto-PGF1 α content and SOD activity, regulated PAl and t-PA activities, ET and NO contents, and decreased MDA content and cells apoptosis rate （P〈0.05 or P〈0.01）. Conclusions： Danhong Injection and its main components played an important
